Mylan looks to hit Teva where it hurts, eyeing slow-release MS treatment

pharmafile | April 11, 2018 | News story | Research and Development, Sales and Marketing Copaxone, Mapi Pharma, Mylan, Teva, biotech, drugs, pharma, pharmaceutical 

Mylan has taken several steps recently that seem intended to hit sales of its big rivals on their key products, first looking at a Botox equivalent and now it has been revealed that it has signed a deal that could see a slow-release Copaxone competitor enter the market.

The partnership involves Mylan teaming up with Israeli-firm, Mapi Pharma, whose lead product is GA Depot, a long-acting Glatiramer Acetate treatment for relapsing-remitting multiple sclerosis. Its major strength over Copaxone is that it could be administered only once a month, should it be approved – this compares favourably to the three-doses per week required by Copaxone.

It was announced that the two companies are preparing to begin recruiting for a Phase 3 trial, as well as beginning the process that will see them apply for IND at the FDA.

Should the drug come through the Phase 3 trial meeting its endpoints then it could likely decimate sales of Copaxone and any generic competitors, including Mylan’s own product.

The financial details of the move were not revealed but Haaretz suggested that $20 million would exchange hands initially.

Mylan President Rajiv Malik commented: “Improving the lives of MS patients around the world is one of Mylan’s primary goals. We recognize that medication convenience is very important to the MS community, and we believe that GA Depot, once approved, will provide an important and welcomed treatment option. GA Depot also will add to our already-strong portfolio of central nervous system products. We appreciate the opportunity to work with Mapi Pharma and its successful and proven founder, Ehud Marom, and we believe that our teams are well poised for a successful collaboration as we work through the remaining clinical and regulatory phases to bring this important product to market.”

The financial backing offered by Mylan means that the biotech seems to have averted its decision to go public in the order to secure short-term funding, after it halted a planned $50 million offering.

Ehud Marom, CEO and Chairman of Mapi, commented, “As one of Israel’s leading biotech companies, we are pleased and excited to have partnered and collaborated with Mylan in bringing this very important new product to the millions of MS patients around the globe. GA Depot is expected to significantly improve the mode of treatment for patients with MS by reducing the number of injections, easing the treatment burden and increasing patient compliance. We look forward to working with Mylan to bring this important drug to MS patients.”

Ben Hargreaves

Related Content

FDA approves IMIDEX’s AI-powered device VisiRad XR

The technological pharmaceutical company IMIDEX has been granted clearance from the US Food and Drug …

Artiva Biotherapeutics announces FDA clearance of IND for AlloNK and Rituximab combo

On 16 August 2023, the US Food and Drug Administration (FDA) officially cleared Artiva Biotherapeutics’ …

Zumutor’s cancer drug trial cleared by FDA

On 11 August 2023, the biopharmaceutical company Zumutor Biologics announced that the trial of its …

Latest content